dc.contributor.author
Kraft, Magdalena
dc.contributor.author
Knop, Macarena Pia
dc.contributor.author
Renaudin, Jean‐Marie
dc.contributor.author
Scherer Hofmeier, Kathrin
dc.contributor.author
Pföhler, Claudia
dc.contributor.author
Bilò, Maria Beatrice
dc.contributor.author
Lang, Roland
dc.contributor.author
Treudler, Regina
dc.contributor.author
Wagner, Nicola
dc.contributor.author
Spindler, Thomas
dc.contributor.author
Hourihane, Jonathan O'B
dc.contributor.author
Maris, Ioana
dc.contributor.author
Koehli, Alice
dc.contributor.author
Bauer, Andrea
dc.contributor.author
Lange, Lars
dc.contributor.author
Müller, Sabine
dc.contributor.author
Papadopoulos, Nikolaos G.
dc.contributor.author
Wedi, Bettina
dc.contributor.author
Moeser, Anne
dc.contributor.author
Ensina, Luis F.
dc.contributor.author
Fernandez‐Rivas, Montserrat
dc.contributor.author
Cichocka‐Jarosz, Ewa
dc.contributor.author
Christoff, George
dc.contributor.author
Garcia, Blanca E.
dc.contributor.author
Poziomkowska‐Gęsicka, Iwona
dc.contributor.author
Cardona, Victoria
dc.contributor.author
Mustakov, Tihomir B.
dc.contributor.author
Rabe, Uta
dc.contributor.author
Mahler, Vera
dc.contributor.author
Grabenhenrich, Linus
dc.contributor.author
Dölle‐Bierke, Sabine
dc.contributor.author
Worm, Margitta
dc.date.accessioned
2022-04-27T13:19:38Z
dc.date.available
2022-04-27T13:19:38Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/34886
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-34605
dc.description.abstract
Background: Patients with a history of anaphylaxis are at risk of future anaphylactic reactions. Thus, secondary prevention measures are recommended for these patients to prevent or attenuate the next reaction.
Methods: Data from the Anaphylaxis Registry were analyzed to identify secondary prevention measures offered to patients who experienced anaphylaxis. Our analysis included 7788 cases from 10 European countries and Brazil.
Results: The secondary prevention measures offered varied across the elicitors. A remarkable discrepancy was observed between prevention measures offered in specialized allergy centers (84% of patients were prescribed adrenaline autoinjectors following EAACI guidelines) and outside the centers: Here, EAACI guideline adherence was only 37%. In the multivariate analysis, the elicitor of the reaction, age of the patient, mastocytosis as comorbidity, severity of the reaction, and reimbursement/availability of the autoinjector influence physician's decision to prescribe one.
Conclusions: Based on the low implementation of guidelines concerning secondary prevention measures outside of specialized allergy centers, our findings highlight the importance of these specialized centers and the requirement of better education for primary healthcare and emergency physicians.
en
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject
adrenaline autoinjector
en
dc.subject
anaphylactic reaction
en
dc.subject
epinephrine autoinjector
en
dc.subject
secondary prevention
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1111/all.14069
dcterms.bibliographicCitation.journaltitle
Allergy
dcterms.bibliographicCitation.number
4
dcterms.bibliographicCitation.originalpublishername
Wiley
dcterms.bibliographicCitation.pagestart
901
dcterms.bibliographicCitation.pageend
910
dcterms.bibliographicCitation.volume
75
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
DEAL Wiley
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
31584692
dcterms.isPartOf.eissn
1398-9995